Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $1,123,200.00 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Collegium Pharmaceutical Stock Down 3.0 %

Shares of NASDAQ COLL opened at $28.91 on Friday. The stock has a 50-day moving average price of $30.78 and a two-hundred day moving average price of $33.21. Collegium Pharmaceutical, Inc. has a 12 month low of $27.28 and a 12 month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $910.26 million, a price-to-earnings ratio of 12.46 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on COLL. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Piper Sandler reduced their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Collegium Pharmaceutical by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock worth $1,902,000 after purchasing an additional 7,063 shares during the period. Velan Capital Investment Management LP bought a new position in Collegium Pharmaceutical in the 4th quarter worth about $822,000. Vident Advisory LLC boosted its stake in Collegium Pharmaceutical by 27.8% in the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock worth $484,000 after purchasing an additional 3,672 shares during the period. Finally, Virtus Fund Advisers LLC boosted its position in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 565 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.